

Job Description – In Vivo Scientist

Responsibilities:

- Lead the in vivo pharmacology aspect of multiple projects within discovery and development, provide in vivo physiology and pharmacology expertise
- Propose, plan, coordinate and supervise study execution at external CROs and academic collaborations
- Develop and implement new animal models to improve the *in vivo* pharmacology study efficacy
- Plan and conduct *in vivo* pharmacology studies: formulation and administration of medical cell products and experimental compounds by various routes
- Ability to write IACUC protocols, own compliance with these and other protocols, and identify potential gaps
- Analyze data from in vivo pharmacology and efficacy studies and perform statistical analysis
- Communication of experimental plans and data to multiple cross-functional scientific teams
- Contribute to preparation of study reports, regulatory filings and project presentations
- Maintain excellent written documentation of completed experiments (e.g. electronic lab notebook and study reports)
- Oversee early-career scientists on the team

Qualifications:

- PhD degree in biology, biochemical engineering, or relevant field with at least 2+ years of relevant industry experience
- Knowledge of preclinical and clinical biomarker discovery and development
- Experience with mammalian cell culture, isolation of immune cells from blood and tissue required
- Previous experience with cell and gene therapy is a plus
- Background in immunology/immuno-oncology is a plus
- Extensive experience working with small laboratory animals and well-established hands-on experience with *in vivo* dosing, bleeding, and handling techniques
- Attention to detail, critical analysis of data and troubleshooting abilities
- Good writing and communication skills; ability to understand and communicate scientific information
- Highly collaborative working style, and ability to adapt in a fast-paced environment
- Ability to work with minimal direction to meet objectives and timelines, adapting to changes and priorities in order to fulfill our mission
- Track record of supervising technical staff to lead early-stage projects

About Avenge Bio:

Avenge Bio, Inc. is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte™ platform. The LOCOcyte™ platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of



immune effector molecules in proximity to the tumor. This initiates a robust, local and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers. Avenge Bio was founded in 2019 based upon technology developed in the laboratory of Omid Veischi, Ph.D. and has an exclusive license from Rice University for this technology. To learn more, visit www.avengebio.com